Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is... see more

Recent & Breaking News (EXPM:SPHS)

Identifying Opportunity, Placing Risk - Analyst Notes on Five Star Quality Care, Senomyx, Ring Energy and Sophiris Bio

Accesswire December 18, 2015

MicroCap Report: Grenville (V.GRC) performs, Sophiris Bio (SPHS) deflates

Stockhouse Editorial November 17, 2015

Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint

PR Newswire November 10, 2015

Sophiris Bio Reports Second Quarter Financial Results

Business Wire August 13, 2015

Poseida Therapeutics, Inc., Expands Board of Directors

GlobeNewswire August 5, 2015

Poseida Therapeutics, Inc., Expands Board of Directors

GlobeNewswire August 5, 2015

Sophiris Bio to Present at the LD Micro Invitational Conference

Business Wire May 27, 2015

Sophiris Bio Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study

Business Wire May 26, 2015

Sophiris Bio Reports First Quarter Financial Results

Business Wire May 13, 2015

Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors

Business Wire April 22, 2015

Sophiris Bio to Present at the Needham Healthcare Conference

Business Wire April 2, 2015

Sophiris Bio Reports Fourth Quarter and Full Year Financial Results

Business Wire March 10, 2015

Sophiris Bio to Present at the Leerink Global Healthcare Conference

Business Wire January 29, 2015

Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Business Wire December 15, 2014

Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference

Business Wire November 25, 2014

Sophiris Bio Reports Third Quarter Financial Results

Business Wire November 12, 2014

Sophiris Bio to Present at the Stifel 2014 Healthcare Conference

Business Wire November 7, 2014

Sophiris Bio to Present at the 13th Annual BIO Investor Forum

Business Wire September 30, 2014

Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Business Wire September 2, 2014

Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights

Business Wire August 7, 2014